CTRI/2023/06/053942
Not yet recruiting
未知
Effect of oral levofloxacin prophylaxis in decreasing the incidence of febrile neutropenia (FN) in children receiving intensive chemotherapy for acute leukemia- A randomized,open label trial
It is a institute based PG thesis protocol0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]Health Condition 2: C920- Acute myeloblastic leukemia
- Sponsor
- It is a institute based PG thesis protocol
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Children age between 1 to 14 years receiving intensive chemotherapy for acute leukemia.
- •2\.Written informed consent.
Exclusion Criteria
- •1\. Standard risk ALL
- •2\. Patient on systemic antibiotics at the time of enrollment except septran prophylaxis
- •3\.Known allergy to quinolones
- •4\.Known case of arthritis
- •5\.Relapse case of acute leukemia
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Evaluation of the effect of oral levofloxacin on chronic endometritis in patientsIRCT20220413054524N1Shahre-kord University of Medical Sciences60
Recruiting
Phase 3
The effectiveness of levofloxacin in prevention of febrile episodes in non-Hodgkin lymphoma patients receiving R-CHOPFebrile episode in non-Hodgkin lymphomaFebrile episodeNon-Hodgkin lymphomaLevofloxacinR-CHOPTCTR20230719005Ratchadapisek Research Funds72
Not yet recruiting
Phase 2
evofloxacin in treatment of tuberculosis infection of brain in childreHealth Condition 1: A170- Tuberculous meningitisCTRI/2024/07/070282All India Institute of Medical Sciences, Rishikesh
Completed
Phase 2
Comparing the effect of levofloxacin with azithromycin in improving pulmonary function of patients with bronchiectasisIRCT20100102002954N28Shahroud University of Medical Sciences72
Active, not recruiting
Phase 1
Efficiency of an antibioprophylaxy (levofloxacin) in patient treated by azacitidinemyelodysplastic syndrome or acute myeloid leukeamiaTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2017-000445-51-FRCentre Henri Becquerel108